Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more
Scancell Hldgs Plc (SCLP) - Total Assets
Latest total assets as of October 2025: GBX15.38 Million GBX
Based on the latest financial reports, Scancell Hldgs Plc (SCLP) holds total assets worth GBX15.38 Million GBX as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scancell Hldgs Plc - Total Assets Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Scancell Hldgs Plc - Asset Composition Analysis
Current Asset Composition (April 2025)
Scancell Hldgs Plc's total assets of GBX15.38 Million consist of 89.3% current assets and 10.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 73.2% |
| Accounts Receivable | GBX3.73 Million | 16.2% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.62 Million | 7.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scancell Hldgs Plc's current assets represent 89.3% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 73.2% of total assets in 2025, up from 60.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 16.2% of total assets.
Scancell Hldgs Plc Competitors by Total Assets
Key competitors of Scancell Hldgs Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Scancell Hldgs Plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Scancell Hldgs Plc generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Scancell Hldgs Plc is currently not profitable relative to its asset base.
Scancell Hldgs Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.43 | 3.99 |
| Quick Ratio | 0.56 | 0.43 | 4.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-10.48 Million | GBX -17.99 Million | GBX 21.07 Million |
Scancell Hldgs Plc - Advanced Valuation Insights
This section examines the relationship between Scancell Hldgs Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.89 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | GBX23.09 Million |
| Market Capitalization | $15.47K USD |
Valuation Analysis
Below Book Valuation: The market values Scancell Hldgs Plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Scancell Hldgs Plc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Scancell Hldgs Plc (2005–2025)
The table below shows the annual total assets of Scancell Hldgs Plc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | GBX23.09 Million | -2.06% |
| 2024-04-30 | GBX23.58 Million | -22.11% |
| 2023-04-30 | GBX30.27 Million | -38.30% |
| 2022-04-30 | GBX49.06 Million | +456.34% |
| 2021-04-30 | GBX8.82 Million | -16.36% |
| 2020-04-30 | GBX10.54 Million | 0.00% |
| 2019-04-30 | GBX10.54 Million | -27.98% |
| 2018-04-30 | GBX14.64 Million | +108.17% |
| 2017-04-30 | GBX7.03 Million | -33.47% |
| 2016-04-30 | GBX10.57 Million | +43.63% |
| 2015-04-30 | GBX7.36 Million | -23.47% |
| 2014-04-30 | GBX9.61 Million | +77.81% |
| 2013-04-30 | GBX5.41 Million | -25.48% |
| 2012-04-30 | GBX7.26 Million | +52.50% |
| 2011-04-30 | GBX4.76 Million | -26.80% |
| 2010-04-30 | GBX6.50 Million | +19.90% |
| 2009-04-30 | GBX5.42 Million | +377.39% |
| 2008-04-30 | GBX1.14 Million | -30.67% |
| 2007-04-30 | GBX1.64 Million | +181.90% |
| 2006-04-30 | GBX581.00K | -53.03% |
| 2005-08-31 | GBX1.24 Million | -- |